Diabetes drug could help rare kidney disease patients
NCT ID NCT06420167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether dapagliflozin, a diabetes drug, is safe and can lower high urine protein levels in people with renal AL amyloidosis—a rare condition where abnormal proteins damage the kidneys. About 20 participants will take the drug daily for 6 months and be monitored via telemedicine. The main goal is to see if at least 30% of patients achieve a 30% drop in protein in their urine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin (a diabetes drug that helps the kidneys)
- What this could lead to
- If it works, this could point toward a new way to reduce kidney damage and protein loss in renal AL amyloidosis patients.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply widely. The drug may not reduce protein levels enough, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States